RxDoctor Payments DataLook up a doctor →

Joel Abbott, DO

Urology · Las Vegas, NVNPI 1720213101

Payments from drug & device makers

$163,561in general payments, 2019–2025

Across 340 payments — averaging $481.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$48K
  • Gyrus ACMI, Inc.$47K
  • Olympus Corporation Of The Americas$47K
  • KARL Storz Endoscopy-america$10K
  • Teleflex LLC$3K
  • Axonics, Inc.$2K
  • plus $7K from 41 others

What the payments were for

  • Consulting fees$22,43832%
  • Speaking & faculty fees$30,10043%
  • Travel & lodging$3,5715%
  • Food & beverage$13,01519%
  • Education$2900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$163,561 in reported general payments places this provider in the 95th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$488,903
Medicare patients
603
Services billed
3,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate14$81,666
GemtesaVibegron95$74,331
MyrbetriqMirabegron80$63,347
Mirabegron ErMirabegron64$59,615
Estradiol157$13,189
Tamsulosin Hcl297$3,146
Solifenacin Succinate80$3,063
Testosterone Cypionate26$1,701
Potassium Citrate ErPotassium Citrate33$1,559
Finasteride151$1,429
Ciprofloxacin Hcl208$617
Oxybutynin Chloride ErOxybutynin Chloride67$398
NitrofurantoinNitrofurantoin Macrocrystal21$314
Chlorthalidone14$279
Oxycodone Hcl69$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$674$74,33195 claims
Astellas Pharma US IncMyrbetriq$678$63,34780 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 urology providers in Nevada.

Other urology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →